Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) is a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. This Form 10-Q covers the quarterly period ended September 30, 2025. The company's portfolio consists of two FDA-approved products: Auryxia (ferric citrate), which lost U.S. exclusivity in March 2025, and Vafseo (vadadustat), which entered the U.S. market in January 2025 for the treatment of anemia in dialysis-dependent chronic kidney disease (CKD) patients.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $58.8 million | $37.4 million | $178.6 million | $113.7 million |
| Net Income (Loss) | $0.5 million | ($20.0 million) | $6.9 million | ($46.6 million) |
| Operating Income (Loss) | $4.4 million | ($12.5 million) | $32.1 million | ($36.2 million) |
| Cash and Cash Equivalents | $166.4 million | $51.9 million | $166.4 million | $51.9 million |
| Long-Term Debt (Net) | $47.6 million | $38.7 million | $47.6 million | $38.7 million |
| Stockholders' Equity | $41.6 million | ($49.2 million) | $41.6 million | ($49.2 million) |
Revenue Breakdown (Q3 2025): Product revenue was $56.8 million, driven by $42.5 million from Auryxia and $14.3 million from Vafseo. License and collaboration revenue was $2.0 million.
Liquidity: The company reported a cash balance of $166.4 million as of September 30, 2025, an increase from $51.9 million at year-end 2024, primarily due to a public offering and debt drawdowns.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported net income of $0.5 million for Q3 2025, a significant improvement from a net loss of $20.0 million in Q3 2024. This was driven by a 57% increase in total revenue and the elimination of intangible asset amortization expense ($9.0 million in Q3 2024 vs. $0 in Q3 2025).
- Revenue Growth: Total revenue increased 57% year-over-year. Vafseo contributed $14.3 million in Q3 2025, whereas it had no revenue in Q3 2024. Auryxia revenue increased 19% to $42.5 million despite the March 2025 loss of exclusivity (LoE).
- Expense Increases: Research and Development (R&D) expenses rose 76% to $14.9 million, and Selling, General, and Administrative (SG&A) expenses increased 10% to $29.1 million, reflecting the commercial launch of Vafseo and increased headcount.
- Debt and Financing: The company drew the final tranche ($10.0 million) of its BlackRock Credit Agreement in February 2025. Additionally, a public offering in March 2025 generated net proceeds of approximately $48.1 million.
Guidance, Outlook, and Risks
Management Commentary: Management believes current cash resources are sufficient to fund operations for at least twelve months. The company is focused on the commercialization of Vafseo and managing the transition of Auryxia following the entry of generic competition. Management noted that the ESRD bundle payment dynamics may result in a slower revenue decline for Auryxia than typical LoE scenarios.
Outlook and Strategic Shifts:
- Vafseo Label Expansion: Following a Type C meeting with the FDA, the company does not plan to initiate the VALOR clinical trial for non-dialysis dependent CKD patients at this time, citing a lack of alignment on trial design. They may explore a smaller subgroup of non-dialysis patients in the future.
- Auryxia Competition: An authorized generic version of Auryxia has been sold since March 2025. The company is monitoring the impact of additional generic entrants and pricing pressures.
Key Risks and Contingencies:
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to inventory accounting and sales forecasting as of December 31, 2024. Remediation efforts are ongoing.
- Debt Covenants: The BlackRock Credit Agreement requires maintaining either a minimum cash balance of $15.0 million or trailing twelve-month revenue of $150.0 million. Failure to meet these could trigger an event of default.
- Supply Chain: The company relies on third-party manufacturers in China, Europe, and Canada. Geopolitical tensions and trade policies (including potential tariffs on Chinese biotech firms) pose supply chain risks.
- Reimbursement: Ongoing litigation regarding the inclusion of oral phosphate binders in the ESRD bundle could impact Auryxia revenue if the bundle is challenged successfully.
Investor Verification Checklist
- Inventory Valuation: Verify the remediation of the material weakness regarding inventory accounting and the accuracy of excess inventory reserves, given the recent LoE for Auryxia.
- Vafseo Adoption Rates: Monitor quarterly Vafseo revenue growth and patient discontinuation rates to assess market acceptance against the $1 billion market opportunity.
- Auryxia Revenue Trajectory: Track Auryxia revenue trends post-LoE to determine the impact of the authorized generic and potential future generic entrants.
- Debt Covenant Compliance: Confirm continued compliance with the BlackRock Credit Agreement's cash and revenue covenants.
- Regulatory Status: Monitor the status of the Ardelyx litigation regarding the ESRD bundle and any updates on Vafseo label expansion discussions with the FDA.